Leading Medical Nutrition Company Masela Completes Nearly RMB 200 Million Series B Financing

Recently, Methuselah (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Methuselah") announced the completion of its Series B financing round, raising nearly RMB 200 million. The round was jointly led by funds under CICC Capital Operation Co., Ltd., Ariose Capital Management Limited, and HLC, with participation from Borchid Capital and FreeS Fund. WinX Capital served as the exclusive financial advisor.This round of financing has garnered strong recognition and robust support from renowned investment institutions and existing shareholders. The funds raised will be primarily used to accelerate the development of a series of medical nutrition products, further expand the company’s scale and competitive lead in its three core business segments—specialized medical nutrition, energy control, and DGI-based blood sugar management—and expedite the fulfillment of its corporate mission to make medical nutrition universally accessible.

China’s medical nutrition industry is still in its early stages of development. Based on the current supply-demand dynamics and global industry trends, medical nutrition is poised to become one of the most promising sectors in China over the next three decades. The Company believes that China’s medical nutrition industry exhibits three distinct characteristics:First, there is substantial market demand that remains largely unmet. Statistics show that China has 245 million patients with hypertension, 130 million with diabetes, and 200 million with hyperlipidemia. In 2024, a total of 52.8 million surgical procedures were performed, and nearly 5 million new cancer cases were diagnosed. These populations—patients with chronic diseases, post-operative patients, and cancer patients—urgently require professional medical nutrition products and services for health intervention. However, there is a significant gap in the current supply system. Although more than 200 registration certificates for Foods for Special Medical Purpose (FSMP) have been approved, product homogenization is a prominent issue. Notably, only one FSMP product specifically formulated for complete nutritional support in cancer patients has been approved, which is insufficient to meet actual clinical needs.Second, the healthy development of the industry urgently requires continuous improvement of the policy framework. Given that medical nutrition directly impacts patient health and survival, the sector faces stringent regulatory standards. With the successive introduction of various national supporting policies, the implementation of reasonable charging mechanisms in medical institutions will effectively unlock the development potential of China’s FSMP market, propelling the industry into a period of rapid growth.Finally, a shortage of professional talent constrains the development of China’s medical nutrition industry. Currently, most tertiary hospitals face a scarcity of clinical nutrition specialists, while FSMP enterprises generally lack sufficient R&D and academic personnel. Only by building a specialized talent pipeline can companies seize opportunities as the industry develops and achieve leapfrog growth.

After more than a decade of development, the company has launched dozens of foods for special medical purposes (FSMP) and special dietary products, maintaining a leading position in China in terms of market share and sales volume within the hospital channel for medical nutritional products. Methuselah has joined forces with multiple clinical nutrition expert teams across China to deeply cultivate the FSMP sector with precision, developing a series of medical nutritional products tailored to the characteristics of the Chinese population. Adhering to the philosophy of “different nutrition for different diseases,” the company has completed its product portfolio layout for complete nutrition targeting various specific diseases.

The company’s two major product lines, “DGI” and “Energy Control,” are respectively dedicated to the research and development, production, and sales of low-glycemic-index foods and medical nutrition products for weight management, encompassing hundreds of SKUs. Leveraging superior quality, excellent taste, and precise market positioning, the company’s products have successfully entered well-known large-scale retail chains such as Sam’s Club, Costco, and Bailian Group, directly reaching a vast consumer base. Committed to continuous innovation, the company launches market-sensing blockbuster products each year based on market dynamics, consumer feedback, and cutting-edge scientific research, further solidifying its leading position in the retail sector of medical nutrition.

In 2025, the company will also launch more innovative products and plan to expand into broader markets, providing hospital and retail partners with more medical nutrition products of clinical value.

Methuselah founder Tang Liming stated:We extend our sincere gratitude to the investors in this round for their recognition of Methuselah, and we also thank WinX Capital for its professional services. We are a group of dedicated pioneers in the field of medical nutrition, driven by a profound passion for our mission and having advanced steadily on our path of exploration for over a decade. Looking ahead, Methuselah will continue to deepen its expertise in medical nutrition, leveraging medical-grade products and specialized services to drive synergistic growth in both clinical healthcare and public health. We are committed to contributing to the development of China’s medical nutrition industry and enhancing the health and longevity of patients and the general public. Our vision is to make medical nutrition accessible worldwide!

CICC Capital stated:CICC Capital’s investment in Methuselah marks another significant step in its deep engagement with the innovative ecosystem of the broader health industry. As a leader in the field of high-end foods for special medical purposes (FSMP) and nutritional science, Methuselah continues to drive upgrades in clinical nutrition therapy and health management services, leveraging its globally leading R&D capabilities, differentiated product portfolio, and advantages in professional medical channels. This investment will fully leverage CICC Capital’s industrial insights and resource integration strengths in the healthcare sector, helping the company expand its market boundaries and empower high-quality development of the medical industry through the synergy of capital and innovation.

Ariose Capital stated:Methuselah is a leading medical nutrition enterprise in China. Following this round of financing, it will further expand its synergistic advantages across three core business segments: specialized medical nutrition, DGI-based blood sugar management, and energy control. Ariose Capital Management Limited highly recognizes the company’s professional team and advanced philosophy, and looks forward to establishing comprehensive cooperation with Methuselah to jointly realize the vision of making medical nutrition accessible worldwide.

HLC stated:HLC Deepens Its Footprint in Medical Nutrition, to Build Robust Synergies Among Portfolio Companies Following Latest Investment in MethuselahLeveraging its domestic and international healthcare industry resources, HLC will provide multi-tiered support to empower its portfolio companies, accelerate Methuselah’s global expansion, and establish it as a leading medical nutrition brand with international influence.

Borchid Capital stated:We are delighted to participate in Methuselah’s current financing round. With the aging population and growing public awareness of preventive health, consumer demand for nutritional management is increasing. Having deeply cultivated the field of medical nutrition for many years, the company has accumulated extensive experience in product R&D and channel management for foods for special medical purposes (FSMP). It has also extended its medical-grade product capabilities to the general wellness sector, developing product lines such as low-GI and weight-management solutions. We believe that Methuselah will continue to launch high-quality products in the medical nutrition space, becoming an innovative brand that represents professional healthcare and health-focused food solutions.

FreeS Fund stated:As Methuselah’s lead institutional investor in its Series A round, FreeS Fund has been deeply involved in the company’s strategic development since the inception of its financing journey and has now completed a third round of additional investment. This capital injection not only underscores our strong recognition of the forward-looking nature of Methuselah’s strategic layout but also reflects our firm confidence in the long-term growth prospects of China’s medical nutrition industry. Methuselah is the only medical nutrition enterprise in China that has achieved synergistic development across three major product lines: foods for special medical purposes (FSMP), low-glycemic index (low-GI) foods, and energy-controlled foods. We are highly optimistic about Methuselah’s potential for sustained future growth. Leveraging FreeS Fund’s extensive industry-academia-research resources accumulated over many years in the biopharmaceutical sector, we will continue to support Methuselah in expanding its market footprint and accelerating the high-quality development of China’s medical nutrition industry.

WinX Capital stated:It is our honor to support Methuselah in completing this round of financing. The company’s founder, Mr. Tang Liming, brings extensive entrepreneurial experience in the healthcare industry. Over more than a decade of development, Methuselah has emerged as a leading enterprise in the field of medical nutrition and has successfully expanded across multiple business dimensions. We believe that under Mr. Tang’s leadership and with the support of its shareholders, Methuselah will grow into a top-tier domestic and world-leading medical nutrition company, driving the Chinese medical nutrition industry to new heights.

CICC Capital is the private equity fund management platform of China International Capital Corporation Limited (“CICC”), overseeing CICC’s domestic and overseas private equity fund businesses. It has developed into one of China’s leading private investment management institutions. Currently, the funds managed by CICC Capital cover a range of types, including RMB corporate equity investment funds, funds of funds (FOFs), infrastructure funds, and USD corporate equity investment funds.

Ariose Capital focuses on equity investments in the healthcare and medical industry. Its limited partners include more than ten publicly listed healthcare companies, state-owned enterprises, market-oriented fund-of-funds, and local governments. Ariose Capital distinguishes itself through two core strengths: its “Ecosystem Investment Strategy” and “Comprehensive Post-Investment Value-Added Services.” By leveraging the advantageous resources of industry-listed companies and professional teams, Ariose Capital builds a robust medical ecosystem and conducts in-depth investment deployments closely aligned with ecosystem resources. Meanwhile, it fully utilizes these ecosystem resources to provide a series of post-investment value-added services to portfolio companies, facilitating their growth and delivering superior returns to the fund’s investors.

Serving China’s modernization, HLC is dedicated to discovering and realizing the enduring value of science and technology. Leveraging deep expertise in core fields such as chemistry, biology, and materials engineering, and grounded in independent, in-depth research and systematic empowerment services, HLC is committed to creating sustained positive impact on productivity transformation and the enhancement of public health through long-term value investments in the real economy and technological innovation. To date, HLC has invested in more than 120 high-quality enterprises, including Mindray Medical, United Imaging Healthcare, Yuwell Medical, Tigermed, Baiyang Pharmaceutical, Pharmaron, Borui Bio, Yikolai Biotech, Kaiyin Technology, Jianhui Information, and Babo.

Borchid Capital is a boutique venture capital firm focused on early- to mid-stage investments in new consumption and consumer technology innovation. Committed to investing in the vision of a better life, it strives to be the earliest discoverer of value and a key long-term partner for entrepreneurs. It has made exclusive or lead early-stage investments in companies such as POP MART, Beneunder, Dailies Contact Lenses, Fanyuan Technology, NEIWAI, moodytiger, Duanmu Liangjin, Xunmeng Technology, SparkX, Huamei Haolian, Yuanding Intelligence, and Oladance.

Frees Fund adheres to an investment strategy focused on interdisciplinary studies and frontier technologies, committed to mobilizing all available capital, technology, and resources to invest in outstanding startups and help them grow into great enterprises with long-term social and commercial value. Frees Fund’s key investment areas include deep tech, biomedicine, and consumption upgrades, covering fields such as intelligent manufacturing, sensors and chips, vertical applications of artificial intelligence, new materials and new energy, biotechnology and novel drug R&D, consumption upgrades, enterprise services, and fintech. Its portfolio includes Three Squirrels (300783.SZ), 360 DigiTech (QFIN), Unity (U.N.), XtalPi (2228.HK), Qingtao Energy, Saturnbird Coffee, Bluepha, and other companies.

WinX Capital is a leading investment bank in China’s healthcare industry, headquartered in Beijing and Shanghai, with offices in Shenzhen and Hangzhou. It has received numerous accolades, including Qimingpian’s “No. 1 Financial Advisor in the Healthcare Sector for 2024,” First New Voice’s “No. 1 Financial Advisory Firm in the Healthcare Sector for 2022 and 2023,” and VCBeat’s “Annual Healthcare Financial Advisor” as part of the “Top 100 Future Healthcare Companies (2022–2024).”